Free Trial

Tarsus Pharmaceuticals (TARS) Competitors

Tarsus Pharmaceuticals logo
$44.10 +1.45 (+3.40%)
Closing price 06/5/2025 04:00 PM Eastern
Extended Trading
$44.09 -0.01 (-0.02%)
As of 06/5/2025 05:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TARS vs. BPMC, BBIO, ELAN, VRNA, TLX, GRFS, TGTX, LEGN, NUVL, and AXSM

Should you be buying Tarsus Pharmaceuticals stock or one of its competitors? The main competitors of Tarsus Pharmaceuticals include Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), Elanco Animal Health (ELAN), Verona Pharma (VRNA), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Grifols (GRFS), TG Therapeutics (TGTX), Legend Biotech (LEGN), Nuvalent (NUVL), and Axsome Therapeutics (AXSM). These companies are all part of the "pharmaceutical products" industry.

Tarsus Pharmaceuticals vs.

Blueprint Medicines (NASDAQ:BPMC) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, community ranking, institutional ownership, earnings, analyst recommendations, valuation and dividends.

90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. 4.2% of Blueprint Medicines shares are held by insiders. Comparatively, 9.0% of Tarsus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Blueprint Medicines received 499 more outperform votes than Tarsus Pharmaceuticals when rated by MarketBeat users. However, 67.90% of users gave Tarsus Pharmaceuticals an outperform vote while only 67.15% of users gave Blueprint Medicines an outperform vote.

CompanyUnderperformOutperform
Blueprint MedicinesOutperform Votes
554
67.15%
Underperform Votes
271
32.85%
Tarsus PharmaceuticalsOutperform Votes
55
67.90%
Underperform Votes
26
32.10%

Blueprint Medicines currently has a consensus price target of $129.71, indicating a potential upside of 1.41%. Tarsus Pharmaceuticals has a consensus price target of $66.67, indicating a potential upside of 51.17%. Given Tarsus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Tarsus Pharmaceuticals is more favorable than Blueprint Medicines.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Blueprint Medicines
0 Sell rating(s)
15 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.33
Tarsus Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
3.00

In the previous week, Blueprint Medicines had 63 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 76 mentions for Blueprint Medicines and 13 mentions for Tarsus Pharmaceuticals. Tarsus Pharmaceuticals' average media sentiment score of 0.91 beat Blueprint Medicines' score of 0.25 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Blueprint Medicines
18 Very Positive mention(s)
14 Positive mention(s)
26 Neutral mention(s)
5 Negative mention(s)
0 Very Negative mention(s)
Neutral
Tarsus Pharmaceuticals
5 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Blueprint Medicines has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500. Comparatively, Tarsus Pharmaceuticals has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500.

Blueprint Medicines has a net margin of -13.19% compared to Tarsus Pharmaceuticals' net margin of -103.64%. Tarsus Pharmaceuticals' return on equity of -55.86% beat Blueprint Medicines' return on equity.

Company Net Margins Return on Equity Return on Assets
Blueprint Medicines-13.19% -77.49% -20.84%
Tarsus Pharmaceuticals -103.64%-55.86%-39.28%

Blueprint Medicines has higher revenue and earnings than Tarsus Pharmaceuticals. Blueprint Medicines is trading at a lower price-to-earnings ratio than Tarsus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Blueprint Medicines$562.12M14.69-$67.09M-$2.47-51.78
Tarsus Pharmaceuticals$233.67M7.93-$135.89M-$2.73-16.15

Summary

Blueprint Medicines and Tarsus Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

Get Tarsus Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for TARS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TARS vs. The Competition

MetricTarsus PharmaceuticalsBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$1.85B$3.05B$5.46B$8.49B
Dividend YieldN/A1.60%5.26%4.19%
P/E Ratio-11.5732.1527.1119.88
Price / Sales7.93450.75410.33155.50
Price / CashN/A168.6838.2534.64
Price / Book7.413.356.884.60
Net Income-$135.89M-$72.17M$3.23B$247.54M
7 Day Performance2.70%5.36%2.97%1.82%
1 Month Performance-5.06%13.33%9.33%8.90%
1 Year Performance36.57%-18.01%27.98%9.82%

Tarsus Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TARS
Tarsus Pharmaceuticals
2.7677 of 5 stars
$44.10
+3.4%
$66.67
+51.2%
+31.2%$1.85B$233.67M-11.5750Gap Down
BPMC
Blueprint Medicines
0.9108 of 5 stars
$101.50
+1.2%
$126.56
+24.7%
+20.9%$6.56B$562.12M-93.98640Trending News
Analyst Downgrade
BBIO
BridgeBio Pharma
4.3834 of 5 stars
$33.34
+1.1%
$57.09
+71.2%
+36.9%$6.33B$127.42M-11.70400
ELAN
Elanco Animal Health
2.0464 of 5 stars
$12.66
-0.1%
$15.17
+19.8%
-27.2%$6.29B$4.43B31.669,800Positive News
VRNA
Verona Pharma
1.6376 of 5 stars
$75.06
+3.3%
$81.50
+8.6%
+604.6%$6.09B$118.54M-39.0930Analyst Forecast
Gap Up
TLX
Telix Pharmaceuticals Limited American Depositary Shares
N/A$16.60
+2.5%
$22.00
+32.5%
N/A$5.61B$783.21M0.00N/ANews Coverage
Analyst Forecast
High Trading Volume
GRFS
Grifols
2.7336 of 5 stars
$8.11
-0.2%
N/A+18.8%$5.58B$7.21B6.9326,300
TGTX
TG Therapeutics
2.9642 of 5 stars
$34.57
+1.0%
$40.80
+18.0%
+137.7%$5.49B$386.39M-345.67290Positive News
LEGN
Legend Biotech
3.3026 of 5 stars
$28.91
-0.5%
$76.20
+163.6%
-27.9%$5.31B$728.30M-30.431,070Gap Up
NUVL
Nuvalent
2.2933 of 5 stars
$73.49
+0.4%
$115.50
+57.2%
+6.1%$5.26BN/A-21.1840Positive News
AXSM
Axsome Therapeutics
4.7869 of 5 stars
$105.07
+0.7%
$172.14
+63.8%
+49.4%$5.17B$432.16M-17.54380Analyst Forecast

Related Companies and Tools


This page (NASDAQ:TARS) was last updated on 6/6/2025 by MarketBeat.com Staff
From Our Partners